Key clinical point: Patients with Merkel cell carcinoma (MCC) may respond better or worse to immunotherapy depending on how they are immunosuppressed.
Major finding: A total of 18% patients with CLL, 33% with autoimmune disease, 66% with HIV/AIDS and 100% with other hematologic malignancies had an objective response.
Study details: A registry analysis of response rates of 31 patients with MCC and immunosuppression who received immunotherapy.
Disclosures: This study was supported by funding from the MCC Patient Gift Fund, the National Cancer Institute, and a grant from NIH. Ms. Zawacki reports no relevant conflicts of interest.
Zawacki L. SID 2020, Abstract 497.